LOGIN  |  REGISTER
Astria Therapeutics
Cue Biopharma

Fulcrum Therapeutics to Participate in Upcoming December Conferences

November 26, 2024 | Last Trade: US$4.14 0.05 1.22

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:

  • Piper Sandler 36th Annual Healthcare Conference
    December 3, 2024
    Fireside Chat at 12:00 pm ET, Participation link: HERE
    New York, New York
  • Citi 2024 Global Healthcare Conference
    December 4, 2024
    Miami, Florida
  • Evercore ISI 7th Annual HealthCONx Conference
    December 5, 2024
    Miami, Florida

The webcast of the Piper Sandler fireside chat will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcasts will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentations.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it. 
917-680-5608

Astria Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page